Cornforth et al., Biochemical Journal, 1951, vol. 48, p. 591,595
作者:Cornforth et al.
DOI:——
日期:——
Kotake et al., Chemische Berichte, 1952, vol. 85, p. 690
作者:Kotake et al.
DOI:——
日期:——
Topical 0.3% ciprofloxacin vs topical 0.3% ofloxacin in early treatment of Pseudomonas aeruginosa keratitis in a rabbit model
作者:Scott E. LaBorwit、Harold R. Katz、Marc J. Hirschbein、Michael R. Oswald、Lori S. Snyder、Ken S. Schwartz、Irvin E. Herling
DOI:10.1007/s12009-001-0055-4
日期:2001.3
An in vivo prospective study compared the effectiveness of 0.3% ciprofloxacin to 0.3% ofloxacin against Pseudomonas aeruginosa keratitis in rabbits. Ofloxacin-treated corneas yielded an average amount of colony-forming units (CFUs) of P aeruginosa that was statistically significantly higher than that of ciprofloxacin-treated corneas (4.7×104±2.2×103 vs 2.5×103±1.0×102). Thus, ciprofloxacin was more effective than ofloxacin in the early reduction of CFUs in P aeruginosa keratitis in rabbits.
[EN] USE OF TRYPTOPHAN DERIVATIVES FOR PROTEIN FORMULATIONS<br/>[FR] UTILISATION DE DÉRIVÉS DU TRYPTOPHANE POUR FORMULATIONS PROTÉIQUES
申请人:GENENTECH INC
公开号:WO2017117304A1
公开(公告)日:2017-07-06
The invention provides methods and formulations comprising a protein comprising solvent accessible amino acid residues susceptible to oxidation wherein N-acetyl tryptophan (NAT) is used to prevent oxidation of the protein. The invention also provides methods for making such formulations and methods of using such formulations. Methods to measure degradation of NAT in protein formulations are also provided.